Siglec-1/CD169 Antibody [Alexa Fluor® 750]

• Reactivity: Mu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 750

Siglec-1/CD169 Antibody [Alexa Fluor® 750] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse Siglec‑1/CD169
  Thr20-Leu1639
  Accession # Q62230
• Specificity: Detects mouse Siglec‑1/CD169 in direct ELISAs and Western blots. In direct ELISAs, approximately 30% cross-reactivity with recombinant human (rh) Siglec-1 is observed and less than 1% cross-reactivity with rhSiglec-2 and recombinant mo
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Siglec-1/CD169 Antibody [Alexa Fluor® 750]

• CD169
• FLJ00051
• sialic acid binding Ig-like lectin 1, sialoadhesin
• sialoadhesin
• Siglec1
• Siglec-1

Background

Siglecs are sialic acid specific I-type lectins that belong to the immunoglobulin superfamily. Structurally, they are transmembrane proteins with an N-terminal Ig-like V‑set domain followed by varying numbers of Ig-like C2-set domains (1, 2). Mouse Siglec-1, also known as sialoadhesin and CD169, is a 175‑185 kDa glycoprotein that consists of a 1619 amino acid (aa) extracellular domain (ECD) with one Ig-like V‑set domain and 16 Ig-like C2-set domains, a 21 aa transmembrane segment, and a 35 aa cytoplasmic domain (3, 4). Within the ECD, mouse Siglec-1 shares 73% and 83% aa sequence identity with human and rat Siglec-1, respectively. Alternate splicing generates a soluble form of the ECD and a soluble isoform that is truncated following the first three Ig-like domains (3). Siglec-1 expression is restricted to lymph node and spleen macrophages and some tissue macrophages (4). The adhesive function of Siglec-1 is supported by the N-terminal Ig-like domain which shows a selectivity for alpha -2,3-linked sialic acid residues (4‑6). Siglec-1 binds a number of sialylated molecules including the mannose receptor, MGL1, MUC1, PSGL-1, and different glycoforms of CD43 (7‑10). Its binding capacity can be masked by endogenous sialylated molecules (11, 12). The sialylated and sulfated N-linked carbohydrates that modify Siglec-1 itself are required for ligand binding (7, 8). Siglec-1 is expressed on dendritic cells following rhinovirus exposure, and these DC promote T cell anergy (13). It is also induced on circulating monocytes during systemic sclerosis and HIV‑1 infection (14‑16). Siglec-1 can trap HIV‑1 particles for trans-infection of permissive cells (15).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.